The purpose of this study is to compare liquid and tablet buprenorphine formulations.

Condition	Treatment or Intervention	Phase
Heroin Dependence	Drug: Buprenorphine	Phase III

Further Study Details: 

Participants were inducted on either liquid or tablet buprenorphine, in a double-blind, double-dummy manner. They each reached a steady state by the second week, and were scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.

Ages Eligible for Study:  21 Years   -   50 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Currently enrolled in the outpatient protocol comparing liquid and tablet formulations of Buprenorphine. Agreeable to conditions of study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

California
      Friends Research Institute, Los Angeles,  California,  90025,  United States

Study chairs or principal investigators

Walter Ling, M.D.,  Principal Investigator,  Friends Research Institute   

Study ID Numbers:  NIDA-09260-5; P50-09260-5
Record last reviewed:  December 2002
Last Updated:  February 16, 2005
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000302
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08